Saturday 17 October 2026
Export DSGN’s income statement to Excel — free account
Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5.88% and free cash flow fell 7.00%, each against the same quarter a year earlier.
10.31
0.17
−1.62%
Follow DSGN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 12.52 | 6.94 | 1.94 | 2.25 | 2.60 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 43.00 | 26.30 | 10.72 | 7.77 | 10.31 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 20 | 38 | 58 | 58 | 54 | 54 | ||||
| Revenue/emp, $m | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (2) | (8) | (36) | (63) | (67) | (50) | (70) | |||||
| EBT margin, % | — | — | — | 0.00 | (3,663.72) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (2) | (8) | (36) | (63) | (67) | (50) | (70) | |||||
| Depreciation | — | — | — | — | 0 | 0 | (1) | (6) | (6) | (3) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.04) | (0.52) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) | |||||
| Cash flow | — | — | — | 0.00 | (0.55) | (0.64) | (0.92) | (1.05) | (0.76) | (0.95) | |||||
| Capex | — | — | — | 0.00 | 0.00 | (0.03) | (0.02) | 0.00 | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | 0.00 | (0.55) | (0.67) | (0.94) | (1.05) | (0.77) | (0.95) | |||||
| Book value | — | — | — | (0.07) | (0.72) | 8.32 | 5.88 | 4.96 | 4.28 | 3.71 | |||||
| Shares, m | — | — | — | 56 | 16 | 46 | 56 | 56 | 57 | 57 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | ||||
| P/S | — | — | — | — | 2,377.24 | — | — | — | — | — | |||||
| P/B | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | 2,217.54 | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | (57.81) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | (9) | (29) | (51) | (59) | (43) | (54) | ||||
| Capex | — | — | — | — | 0 | (2) | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | 0 | (9) | (31) | (52) | (59) | (43) | (55) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (4) | 34 | 380 | 324 | 275 | 240 | 211 | ||||
| Total debt | — | — | — | 1 | — | 4 | 4 | — | — | — | |||||
| Net debt | — | — | — | 1 | (36) | (384) | (330) | (282) | (245) | (220) | |||||
| Shareholders’ equity | — | — | — | (4) | (11) | 382 | 327 | 278 | 242 | 213 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (4,548.89) | (45.24) | (16.64) | (17.30) | (21.20) | (18.31) | (29.18) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 27.37 | 110.72 | (19.16) | (17.85) | (22.10) | (19.08) | (30.70) | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Dec 2020
Charts ten years each
Design Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $682.2M | 111× | — (loss-making) | −34.73% (below 0%: shrinking) | n/m | −174.83% (below 0%: shrinking) | 68.96% | (28.69%) | Compare |
| CADL Candel Therapeutics, Inc. | $681.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $681.6M | 62.4× | — (loss-making) | −3.22% (below 0%: shrinking) | −57.14% (below 0%: shrinking) | −183.87% (below 0%: shrinking) | 83.92% | 1.44% | Compare |
| GYRE Gyre Therapeutics, Inc. | $678.6M | — (loss-making) | — (loss-making) | −2.12% (below 0%: shrinking) | n/m | −130.45% (below 0%: shrinking) | 92.41% | (49.35%) | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DSGN Design Therapeutics, Inc. | $655.9M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | |
| PRME Prime Medicine, Inc. | $654.8M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | Compare |
| AVTX Avalo Therapeutics, Inc. | $644.1M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| Median of peers | $680.1M | — | — | −2.67% | — | −74.80% | 62.35% | 0.00% |
Design Therapeutics, Inc. (DSGN) key facts
- Concern: Design Therapeutics, Inc. reported a net loss of $69.8 million, or a loss of $1.22 per share, for fiscal 2025.
- Design Therapeutics, Inc. (DSGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, DSGN traded at $10.31, a market capitalization of $655.9 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2,851× sales.
- Return on equity was −30.7% and debt-to-equity 0.00.